Genome Publications
https://doi.org/10.61096/9788199887565_1

CHAPTER 1

Evolution of Drug Delivery: From Conventional Dosage Forms to Precision Therapeutic Platforms

[1]Dr. Nataraj Palaniyappan, [2]Dr. M. Ravisankar

[1]Scientist, Novitium Pharma LLC, New Jersey, USA
[2]Department of Pharmaceutical Chemistry
Srinivasan College of Pharmaceutical Science, Trichy

Abstract

The development of drug delivery science represents one of the most consequential trajectories in modern pharmaceutical and biomedical research, reshaping how therapeutic agents are formulated, administered, and directed to their sites of action. This chapter traces the evolution of drug delivery from early conventional dosage forms—tablets, capsules, and simple parenteral solutions—through successive generations of modified-, sustained-, and controlled-release systems, to the targeted, intelligent, and precision platforms that define the contemporary field. It examines the pharmacological and physicochemical limitations of immediate-release formulations that motivated innovation, including fluctuating plasma concentrations, poor and variable bioavailability, off-target toxicity, and inadequate patient adherence. The discussion follows the conceptual shift from systemic administration toward site-specific targeting, the foundational role of polymer science, and the emergence of transdermal, implantable, and depot technologies. Particular attention is given to nanotechnology as a transformative platform, the rise of biologic and nucleic acid therapeutics that redefined delivery requirements, and the complementary principles of passive and active targeting. The chapter further explores precision medicine, smart and programmable delivery systems, and the convergence of nanotechnology, biotechnology, and computational design. The current translational landscape is reviewed alongside persistent barriers in scale-up, regulation, and commercialization. Recent advances, including lipid nanoparticle–enabled messenger RNA therapeutics and engineered cell-based platforms, illustrate the maturation of the discipline. The chapter concludes by outlining future directions toward fully integrated, patient-specific therapeutic platforms, establishing the conceptual framework that underpins the remainder of this volume.

Keywords: *drug delivery systems, controlled release, targeted delivery, nanotechnology, precision medicine*

1.0 Introduction

The fundamental objective of any therapeutic intervention is to deliver the right drug, at the right concentration, to the right site, for the right duration, while minimizing harm to healthy tissues. For most of pharmaceutical history this objective was approached almost entirely through the molecular optimization of the drug itself, with comparatively little attention paid to how the molecule was carried through the body. Over the past five decades, however, the carrier and the delivery process have become as important as the active agent, and drug delivery has matured into a distinct interdisciplinary science spanning pharmaceutics, materials engineering, molecular biology, and, increasingly, computation [1,4]. This transition reflects a recognition that the therapeutic value of a molecule is determined not only by its intrinsic activity but by its pharmacokinetic behaviour, its ability to reach its target, and its compatibility with the patient's biology and daily life.

The arc of this evolution can be understood as a progression from controlling when and how fast a drug is released, to controlling where it acts, to controlling the response of the delivery system itself to physiological cues. Conventional immediate-release dosage forms gave way to sustained- and controlled-release systems, which were in turn complemented by targeted carriers, stimuli-responsive platforms, and, most recently, precision systems tailored to the molecular and genetic profile of the individual patient [2,3]. Each stage was driven by the limitations of its predecessor and enabled by parallel advances in polymer chemistry, nanoscience, and biotechnology.

This chapter establishes the historical and conceptual foundation for the volume. It surveys the major milestones in the development of drug delivery, articulates the scientific rationale behind each generational shift, and connects these developments to the emerging technologies and therapeutic innovations examined in subsequent chapters. The emphasis throughout is on continuity: contemporary precision platforms are not isolated breakthroughs but the cumulative product of incremental problem-solving across generations of delivery science. Figure 1.1 provides a roadmap of this trajectory.



Figure 1.1. *Roadmap of the evolution of drug delivery, from conventional dosage forms through controlled-release, targeted, smart, and precision platforms, with representative eras and enabling technologies.*

1.1 Historical Development of Conventional Dosage Forms

The earliest dosage forms were extensions of natural products: powders, decoctions, pills compacted by hand, and crude extracts administered orally or topically. The industrialization of pharmacy in the nineteenth and early twentieth centuries introduced standardized tablets, compressed using excipients and binders, alongside capsules, syrups, and the first sterile injectable solutions [5]. These conventional dosage forms were designed primarily to deliver a measured quantity of drug in a reproducible, stable, and palatable manner, and they remain the backbone of pharmaceutical practice because of their low cost, ease of manufacture, and convenience.

Conventional formulations are characterized by immediate release: the drug dissolves rapidly after administration and is absorbed in a single, relatively uncontrolled pulse. For many indications this is entirely adequate, and immediate-release oral tablets continue to dominate global prescriptions. The pharmaceutical sophistication of these products grew steadily through improvements in excipient science, tablet coating, dissolution control, and quality assurance, which together raised the reliability and bioequivalence of generic medicines [5]. Nonetheless, the conventional dosage form treats the body as a passive recipient: once administered, the formulation exerts no further control over the fate of the drug.

By the mid-twentieth century it became clear that this passive paradigm imposed real therapeutic ceilings. Drugs with narrow therapeutic windows, short half-lives, or significant toxicity could not be optimally managed by repeated immediate-release dosing. The recognition of these constraints, together with emerging polymer and materials technologies, set the stage for the first deliberate attempts to engineer the release of a drug rather than merely its dose [2]. The conventional dosage form thus represents both the foundation of pharmaceutics and the baseline against which all subsequent delivery innovations have been measured.

1.2 Limitations of Immediate-Release and Conventional Formulations

The limitations of immediate-release formulations stem largely from their inability to control the temporal and spatial distribution of the drug. After absorption, plasma concentrations rise rapidly to a peak and then decline, producing a characteristic peak-and-trough profile. With repeated dosing, concentrations oscillate, frequently exceeding the upper threshold associated with toxicity and falling below the minimum effective concentration between doses [2,3]. For drugs with narrow therapeutic indices, these fluctuations translate directly into a cycle of adverse effects and subtherapeutic exposure.

A second major limitation is poor and variable bioavailability. Many drug candidates, particularly those emerging from modern discovery pipelines, are poorly water-soluble or poorly permeable, and a substantial fraction of an orally administered dose may never reach the systemic circulation owing to incomplete dissolution, presystemic metabolism, or efflux. Biologic agents face even greater obstacles: peptides and proteins are degraded by gastrointestinal enzymes and are too large to cross epithelial barriers efficiently, effectively precluding conventional oral administration [8]. A third limitation is the absence of selectivity. A systemically distributed drug reaches healthy and diseased tissues alike, so the dose required to achieve a therapeutic concentration at the target site often produces off-target toxicity elsewhere—a constraint that is especially acute in oncology [16,17].

Finally, conventional regimens place a heavy burden on patients. Frequent dosing, complex schedules, and the discomfort of repeated injections all undermine adherence, which is a leading cause of treatment failure in chronic disease. Collectively, these limitations—fluctuating exposure, poor bioavailability, lack of selectivity, and adherence burden—defined the problem space that drug delivery science set out to solve, and they continue to motivate innovation today [1].

Table 1.1. Comparative features of conventional and advanced drug delivery systems.

Attribute	Conventional (immediate-release) systems	Advanced delivery systems
Release profile	Single rapid pulse; peak-and-trough kinetics	Controlled, sustained, or triggered release matched to need

Attribute	Conventional (immediate-release) systems	Advanced delivery systems
Plasma concentration	Fluctuating; frequent excursions outside therapeutic window	Maintained within therapeutic window for prolonged periods
Selectivity	Systemic, non-selective distribution	Passive and/or active targeting to disease sites
Bioavailability	Often low and variable, especially for biologics	Enhanced through protection, solubilization, and permeation
Dosing frequency	Frequent; high adherence burden	Reduced; long-acting and patient-friendly formats
Toxicity	Off-target exposure limits dose	Reduced off-target exposure widens therapeutic index

1.3 Generational Classification of Drug Delivery Systems (First to Fourth Generation)

It is useful to organize the evolution of drug delivery into successive generations, each defined by the dominant design objective of its era. The first generation, spanning roughly the 1950s to the 1980s, focused on controlling the rate and duration of release. Oral sustained-release tablets, osmotic pumps, and the earliest transdermal patches embodied this goal, demonstrating that release kinetics could be engineered through diffusion, dissolution, and osmotic mechanisms [2,3]. The second generation, from the 1980s onward, pursued smart and targeted delivery, introducing nanoparticulate carriers, long-circulating liposomes, and stimuli-responsive materials intended to direct drugs to specific tissues and to release them in response to environmental cues [4,11].

The classification is, of course, a simplification; generations overlap and technologies mature at different rates. The first generation succeeded spectacularly and now underpins a large fraction of marketed controlled-release products, whereas the ambitions of later generations—particularly reliable active targeting in humans—have proven considerably harder to realize than early enthusiasm suggested [3]. A widely cited observation in the field is that the conceptual leap from controlling release to controlling biodistribution required not merely better materials but a far deeper understanding of the biological barriers that carriers must traverse [24].

More recent framing extends the scheme to a third generation, characterized by the modulation of nanocarrier–biology interactions and the rational design of carriers to overcome specific physiological obstacles, and a fourth generation defined by precision and personalization, in which delivery systems are matched to the molecular, genetic, and even temporal characteristics of the individual patient [15,25]. This generational lens, summarized in Figure 1.2 and Table 1.2, provides a coherent narrative for the technical chapters that follow and emphasizes that each generation builds upon, rather than replaces, the achievements of its predecessors.

Table 1.2. Generational classification of drug delivery systems.

Generation	Era (approx.)	Defining objective	Representative technologies
First	1950s–1980s	Control of release rate and duration	Oral sustained-release matrices, osmotic pumps, early transdermal patches

Generation	Era (approx.)	Defining objective	Representative technologies
Second	1980s–2000s	Targeting and stimuli-responsiveness	Long-circulating liposomes, polymeric nanoparticles, pH/thermo-responsive carriers
Third	2000s–2010s	Overcoming biological barriers; nano–bio interactions	Surface-engineered and stealth nanocarriers, antibody-targeted systems
Fourth	2010s–present	Precision and personalization	LNP–mRNA platforms, patient-tailored and programmable systems, cell-based delivery



Figure 1.2. Generational classification of drug delivery systems, illustrating the progression from temporal control of release through spatial targeting and barrier navigation to patient-specific precision.

1.4 Emergence of Modified, Sustained, and Controlled-Release Systems

The first deliberate departure from immediate release was the development of modified-release systems designed to extend the duration of action and smooth the plasma concentration profile. Sustained-release formulations slow the rate of drug release so that absorption is prolonged, reducing dosing frequency, while controlled-release systems aim to maintain a defined, often constant, release rate independent of the surrounding environment [2,7]. The distinction is more than semantic: controlled release implies a predictable, engineered output, whereas sustained release describes a slower but not necessarily constant profile.

Several mechanisms underpin these systems. Diffusion-controlled devices release drug through a polymer matrix or across a rate-limiting membrane; dissolution-controlled systems modulate release through the solubility of the drug or a coating; and osmotically driven systems use water influx to expel drug at a constant rate through a precisely sized orifice. The mathematical description of these processes—through zero-order, first-order, Higuchi, and Korsmeyer–Peppas models—provided the quantitative foundation that allowed formulators to design rather than discover release profiles, and remains central to modern formulation science [7]. The landmark demonstration that macromolecules could be released in a sustained manner from solid polymer matrices was particularly influential, because it showed that even large, fragile molecules could be delivered over weeks rather than hours [6].

Clinically, modified-release technologies delivered substantial benefits: once-daily formulations of cardiovascular, analgesic, and central nervous system drugs improved adherence and tolerability, and osmotic pump tablets achieved remarkably constant delivery for drugs requiring steady plasma levels. The principal limitations are dose-dumping risk if the system fails, the difficulty of accommodating very high doses, and the fact that these systems still distribute the drug systemically. Modified-release technology therefore solved the temporal problem of drug delivery while leaving the spatial problem—selectivity—largely untouched, motivating the conceptual shift toward targeting [1,3].

1.5 Conceptual Shift from Drug Administration to Drug Targeting

The recognition that controlling release was insufficient to overcome systemic toxicity prompted one of the most important conceptual shifts in the history of the field: the move from drug administration to drug targeting. The intellectual origin of this idea is often traced to Paul Ehrlich's notion of a 'magic bullet'—an agent that would seek out and act upon only the diseased target—but its practical realization required carriers capable of altering the natural biodistribution of a drug [14]. Targeting reframed the central question of drug delivery from 'how fast should the drug be released?' to 'where should the drug accumulate, and how can it be kept away from healthy tissue?'

Two complementary strategies emerged. Passive targeting exploits the abnormal physiology of diseased tissue, most famously the enhanced permeability and retention (EPR) effect, whereby the leaky vasculature and impaired lymphatic drainage of many solid tumours permit the preferential accumulation of appropriately sized macromolecules and nanoparticles [16]. Active targeting, by contrast, decorates carriers with ligands—antibodies, peptides, sugars, or small molecules—that bind receptors overexpressed on target cells, promoting selective uptake. These principles, examined in detail in Section 1.10 and in later chapters, transformed delivery from a purely pharmaceutical exercise into one deeply intertwined with cell biology and pathology [17,24].

The shift toward targeting also recalibrated expectations and timelines. Whereas controlled-release products moved relatively quickly from concept to market, targeted systems exposed the formidable complexity of in vivo barriers—opsonization, clearance by the mononuclear phagocyte system, heterogeneous tumour perfusion, and high interstitial pressure—that frustrate the delivery of carriers to their intended destination [24,26]. The conceptual ambition of targeting thus far outpaced its early clinical realization, a tension that continues to shape research priorities and that frames the discussion of biological barriers in Chapter 3.

1.6 Role of Polymer Science in Early Controlled-Release Technologies

Polymer science provided the material foundation on which controlled and targeted delivery were built. Polymers offered tunable mechanical, diffusional, and degradation properties that could be engineered to govern the release of an entrapped drug, and the demonstration that biocompatible polymers could sustain the release of macromolecules established the discipline of polymeric drug delivery [6]. Non-degradable polymers such as silicone and ethylene-vinyl acetate were used in early reservoir and matrix devices, while the introduction of biodegradable polyesters—most importantly poly(lactic-co-glycolic acid) (PLGA) and its homopolymers—allowed the design of systems that release drug as they erode and then disappear, obviating the need for surgical retrieval [13].

Beyond serving as inert matrices, polymers became active participants in delivery. The concept of polymer therapeutics, in which a drug is covalently conjugated to a water-soluble polymer carrier, demonstrated that polymer attachment could prolong circulation, alter biodistribution, and exploit the EPR effect, giving rise to a generation of polymer–drug and polymer–protein conjugates [9]. PEGylation—the attachment of poly(ethylene glycol) to proteins and particles—became a particularly enduring strategy for extending half-life and reducing immunogenicity, and remains in widespread clinical use. The functionalization of polymer surfaces with targeting ligands further enabled the construction of biodegradable, biocompatible nanocarriers capable of directed delivery [36].

The advantages of polymeric systems—versatility, tunability, biodegradability, and scalability—are balanced by limitations including batch-to-batch variability, potential immunogenicity of degradation products, and the challenge of achieving reproducible nanoscale manufacture. Regulatory scrutiny of polymer identity, molecular weight distribution, and degradation kinetics is correspondingly demanding. Nonetheless, polymer science remains indispensable, underpinning not only the early controlled-release devices discussed here but also the nanoparticles, hydrogels, and conjugates examined throughout this volume [23,36].

1.7 Development of Transdermal, Implantable, and Depot Systems

Parallel to advances in oral and injectable controlled release, an important strand of innovation sought to bypass the limitations of these routes entirely through transdermal, implantable, and depot systems. Transdermal patches, first introduced for scopolamine and subsequently for nicotine, nitroglycerin, hormones, and analgesics, deliver drug across the skin at a controlled rate, avoiding first-pass metabolism, smoothing plasma profiles, and improving adherence through infrequent application [10,12]. Their principal constraint is the formidable barrier function of the stratum corneum, which restricts transdermal delivery to relatively potent, lipophilic, low-molecular-weight drugs—a limitation that motivated the later development of microneedles and physical enhancement techniques discussed in Chapter 18 [12].

Implantable and depot systems extend the duration of action from days to months or even years. Subcutaneous implants, in situ–forming gels, and biodegradable microsphere depots provide sustained release of hormones, contraceptives, antipsychotics, and peptides, dramatically reducing dosing frequency and supporting adherence in chronic conditions [13]. Long-acting injectable formulations have become especially significant in psychiatry, contraception, and the prevention and treatment of HIV, where they convert a daily-pill regimen into an injection administered weeks or months apart. These technologies, examined comprehensively in Chapter 15, demonstrate that delivery innovation can transform not only pharmacokinetics but the entire pattern of clinical care.

The advantages of these routes—steady delivery, reduced dosing burden, and avoidance of gastrointestinal and first-pass effects—are weighed against limitations including limited dose capacity, the invasiveness of implantation and retrieval, the risk of injection-site reactions, and the difficulty of halting delivery once a long-acting depot is administered. Their success nonetheless established a durable principle: that the route and physical form of a delivery system are powerful levers for shaping therapy, independent of the drug molecule itself [1].

1.8 Nanotechnology as a Transformative Platform in Drug Delivery

The advent of nanotechnology marked a qualitative transformation in drug delivery, providing carriers whose dimensions—typically tens to hundreds of nanometres—are comparable to biological structures and which can therefore interact with cells and tissues in ways impossible for bulk materials. The discovery that phospholipids spontaneously assemble into closed bilayer vesicles laid the groundwork for liposomes, the first nanocarriers to reach the clinic, while subsequent decades produced an extraordinary diversity of polymeric nanoparticles, micelles, dendrimers, and inorganic carriers [10,14]. Nanocarriers can solubilize poorly soluble drugs, protect labile cargoes from degradation, prolong circulation, and accumulate preferentially in diseased tissue, addressing several limitations of conventional formulations simultaneously [17].

The clinical proof of concept came with long-circulating PEGylated liposomal doxorubicin and related products, which demonstrated that nanoencapsulation could alter biodistribution and reduce the cardiotoxicity of a potent chemotherapeutic [11]. These successes established cancer nanomedicine as a major field and catalyzed intensive investigation of the EPR effect and of strategies to engineer particle size, shape, surface charge, and surface chemistry for optimal in vivo behaviour [16,24]. Inorganic and hybrid platforms—including iron oxide, gold, and mesoporous silica nanoparticles—added imaging, photothermal, and stimuli-responsive capabilities, broadening the functional repertoire of nanocarriers [37].

Nanotechnology also exposed the limits of optimism. Systematic analyses revealed that only a small fraction of an injected nanoparticle dose typically reaches solid tumours in animal models, and that the heterogeneity of the EPR effect in human patients undermines the reliability of passive targeting [24,26]. These sobering findings, rather than discrediting nanomedicine, refined it—shifting emphasis toward rational design, quantitative frameworks for delivery, and applications such as nucleic acid delivery where nanocarriers are not merely advantageous but essential [15,26]. The maturation of nanotechnology from a promising idea to an indispensable platform is one of the defining narratives of modern drug delivery, and it recurs throughout Chapters 4 through 8. The principal milestones of this progression are charted in Figure 1.3.



Figure 1.3. Landmark milestones in the evolution of nanocarrier-based drug delivery, from the discovery of liposomes to lipid nanoparticle–enabled nucleic acid therapeutics.

1.9 Biotechnology and the Rise of Biologic and Nucleic Acid Therapeutics

The biotechnology revolution fundamentally reshaped the demands placed on drug delivery. As therapeutic modalities expanded beyond small molecules to encompass peptides, proteins, monoclonal antibodies, and nucleic acids, the delivery challenges multiplied, because these large, fragile, and often charged molecules are poorly suited to the routes and formulations developed for small molecules [1,8]. Proteins and peptides offer exquisite target selectivity but are rapidly degraded, cleared, and, in the case of oral administration, almost entirely destroyed before absorption; their successful use therefore depended on delivery innovations such as PEGylation, stabilized formulations, and engineered long-acting depots [8].

Nucleic acid therapeutics posed an even more acute delivery problem. Messenger RNA, small interfering RNA, antisense oligonucleotides, and gene-editing tools must reach the interior of target cells intact, yet they are large, negatively charged, immunogenic, and exquisitely sensitive to nucleases, and they cannot cross cell membranes unaided [19,22]. The field's central insight was that for these modalities the delivery system is not an enhancement but a prerequisite: without an effective carrier there is no therapy. Lipid nanoparticles emerged as the breakthrough enabling technology, first validated by the approval of an siRNA therapeutic for hereditary transthyretin amyloidosis and then, dramatically, by their role in the messenger RNA vaccines deployed at global scale during the COVID-19 pandemic [20,21].

The convergence of biotechnology and delivery science also produced cell-based therapeutics, in which living cells—most prominently chimeric antigen receptor (CAR) T cells—are themselves the therapeutic agent, raising entirely new questions about how to deliver, localize, and control living medicines [23]. Comprehensive analyses of commercial delivery technologies have argued that the challenges of each successive therapeutic class—small molecules, then macromolecules, then cells—have repeatedly driven the invention of new delivery paradigms, and that the lessons learned from one modality increasingly inform the next [1]. This co-evolution of cargo and carrier is a recurring theme of the volume, addressed directly in Chapters 12 through 14.

1.10 Active and Passive Targeting for Site-Specific Therapeutic Action

Targeting strategies are conventionally divided into passive and active mechanisms, and understanding their complementary logic is essential to appreciating both the promise and the difficulty of site-specific delivery. Passive targeting relies on the physicochemical properties of the carrier and the pathophysiology of the target tissue. The EPR effect remains the archetype: nanoparticles of appropriate size and surface character extravasate through the discontinuous endothelium of tumour vasculature and are retained owing to impaired lymphatic clearance, producing preferential accumulation without any specific molecular recognition [16,17]. Long circulation, achieved through stealth coatings such as PEG, is a prerequisite for effective passive targeting because it allows repeated passage of the carrier through the leaky vasculature [11]. Figure 1.4 contrasts the two complementary mechanisms of passive and active targeting.

Active targeting superimposes molecular specificity onto this distribution. Carriers are functionalized with ligands that bind receptors or antigens enriched on target cells—folate, transferrin, and a wide array of antibodies and peptides have been employed—so that, once delivered to the vicinity of the target, the carrier is selectively bound and internalized [14,25]. Importantly, active targeting generally improves cellular uptake and retention rather than gross tissue accumulation; the ligand directs the carrier to the right cells after passive processes have brought it to the right neighbourhood. The two mechanisms are therefore synergistic rather than alternative, a nuance often lost in early literature [24,25].

The clinical translation of targeting has been uneven. Passive targeting underlies several approved nanomedicines but is undermined by the heterogeneity of the EPR effect across tumour types and patients, while active targeting has proven difficult to translate owing to manufacturing complexity, ligand stability, and the protein corona that can mask targeting ligands in vivo [24,26]. The most successful embodiment of molecular targeting to date is arguably the antibody–drug conjugate, in which the antibody both targets and delivers, a modality examined in Chapter 14. These experiences have reframed targeting as a problem of overcoming a sequential series of biological barriers rather than a single docking event, a perspective that informs the rational, physiology-led design strategies now ascendant in the field [22,28].



Figure 1.4. Complementary mechanisms of passive (EPR-mediated) and active (ligand–receptor) targeting in tissue accumulation and cellular uptake.

1.11 Precision Medicine and Patient-Specific Delivery Platforms

The contemporary frontier of drug delivery is defined by precision medicine: the tailoring of therapy, including its delivery, to the molecular, genetic, physiological, and lifestyle characteristics of the individual patient. As molecular diagnostics, genomic profiling, and biomarker science have matured, it has become possible not only to select drugs for specific patient subpopulations but to design delivery systems that respond to patient-specific features such as receptor expression, tumour genotype, or disease microenvironment [25,28]. Precision delivery thus extends the logic of targeting from the disease in general to the patient in particular.

Several technologies embody this shift. Personalized dosing through additive manufacturing allows the production of dosage forms with patient-specific doses, drug combinations, and release profiles, as discussed in Chapter 9. Nucleic acid platforms are inherently programmable, since the same lipid nanoparticle carrier can deliver different messenger RNA sequences, enabling rapid customization—a property exploited both in pandemic vaccines and in emerging individualized cancer vaccines [20]. Cell-based therapies are by their nature patient-specific, particularly autologous CAR T cells engineered from a patient's own lymphocytes [23]. Across these examples, the delivery system is increasingly co-designed with the diagnostic and the therapeutic, blurring the historical separation between drug, device, and test.

Precision delivery offers the prospect of maximizing efficacy while minimizing toxicity and avoiding the inefficiency of one-size-fits-all therapy. Its limitations are substantial, however: personalized and cell-based products are costly and complex to manufacture, raise difficult questions of scalability and reimbursement, and challenge regulatory frameworks designed for mass-produced medicines [28,31]. The reconciliation of personalization with accessibility is among the central tensions of the field, returned to in Sections 1.13 and 1.14 and in the concluding chapters of this volume.

1.12 Smart, Responsive, and Programmable Drug Delivery Systems

A further dimension of the modern field is the development of smart, stimuli-responsive, and programmable systems that adjust their behaviour in response to internal or external cues. Whereas controlled-release devices deliver drug according to a predetermined profile, responsive systems release their cargo only when and where a triggering condition is met, in principle achieving far tighter spatial and temporal control [27]. Endogenous triggers include the acidic pH of tumours and endosomes, elevated concentrations of specific enzymes or reducing agents, and disease-associated hypoxia; exogenous triggers include light, heat, magnetic fields, and ultrasound applied by the clinician [27,28].

The appeal of these systems lies in their potential for feedback and selectivity. A glucose-responsive insulin delivery system that releases insulin in proportion to blood glucose, for example, would emulate the physiological function of the pancreas and represents a long-sought goal of closed-loop therapy. Multi-stimuli-responsive and logic-gated designs, which require the coincidence of several signals before releasing drug, promise still greater precision by reducing the likelihood of release at non-target sites [27]. These platforms exploit a detailed understanding of disease physiology, and their rational design depends on the same biological insight that underlies effective targeting [28].

Despite their conceptual elegance, smart systems face significant translational hurdles. Endogenous triggers are often only modestly different between diseased and healthy tissue, limiting selectivity; exogenous triggers require specialized equipment and add procedural complexity; and the multicomponent architectures of responsive carriers complicate manufacturing, characterization, and regulatory approval. Consequently, relatively few stimuli-responsive systems have reached the market despite decades of research [27]. Nonetheless, they constitute one of the most active areas of investigation, and their integration with sensing and computation, discussed in Chapter 20, points toward genuinely autonomous therapeutic systems. Stimuli-responsive delivery is treated comprehensively in Chapter 8.

1.13 Current Translational Landscape of Advanced Drug Delivery

The cumulative result of these developments is a clinical landscape in which advanced delivery systems are no longer experimental curiosities but established components of modern therapeutics. Numerous nanomedicines—liposomal, polymeric, protein-based, and inorganic—have received regulatory approval, and periodic surveys document a steadily expanding portfolio across oncology, infectious disease, and chronic conditions [18,31,32]. The approval of an siRNA therapeutic and, subsequently, the global deployment of lipid nanoparticle–based messenger RNA vaccines represent watershed moments that validated decades of foundational work and demonstrated the capacity of delivery technology to respond to urgent public-health need at unprecedented speed [20,21].

This landscape is characterized by a marked diversification of modalities and delivery paradigms. Comprehensive analyses identify a small number of recurring delivery strategies that underpin most clinical successes, and note that the challenges of each new therapeutic class continue to drive incremental innovation in carriers and formulations [1]. Long-acting injectables have transformed the management of psychiatric illness and HIV; antibody–drug conjugates have become a major class of targeted oncology agents; and cell and gene therapies, though still costly and complex, have moved from concept to approved product [23,25]. Representative examples are summarized in Table 1.3.

Table 1.3. Representative approved advanced delivery systems and the delivery problem each addresses.

Platform / modality	Illustrative application	Delivery problem addressed
PEGylated liposomes	Liposomal doxorubicin in cancer	Reduces cardiotoxicity; prolongs circulation; passive tumour accumulation
Lipid nanoparticles (LNP)	siRNA and mRNA therapeutics and vaccines	Protects and delivers fragile nucleic acids intracellularly
Long-acting injectables	Antipsychotics, contraceptives, HIV prevention	Converts frequent dosing to infrequent injection; supports adherence
Antibody–drug conjugates	Targeted cytotoxic therapy in oncology	Couples molecular targeting with potent payload delivery
Transdermal systems	Hormones, analgesics, nicotine	Avoids first-pass metabolism; steady delivery; convenience
Cell-based therapies	CAR T cells in haematological malignancy	Delivers a living, patient-specific therapeutic agent

Translational maturity has also brought a more realistic appraisal of nanomedicine, with the field increasingly emphasizing robust manufacturing, quality control, and the alignment of delivery technology with genuine clinical need rather than novelty alone [33,38]. The practical impact of drug delivery is now measured not only in new approvals but in improved adherence, reduced toxicity, and the enabling of therapeutic modalities that would otherwise be undeliverable.

1.14 Challenges in Clinical Adoption and Commercial Development

Despite this progress, the path from laboratory innovation to approved, accessible product remains arduous, and a substantial gap persists between the volume of published delivery research and the number of systems that reach patients. A primary obstacle is manufacturing complexity. Advanced delivery systems often comprise multiple components assembled with nanoscale precision, and reproducing this assembly at commercial scale while maintaining critical quality attributes is difficult and costly [34,38]. Scale-up frequently introduces variability that compromises performance, and processes optimized in the laboratory may not transfer cleanly to industrial production.

Regulatory uncertainty compounds the challenge. Complex products that blur the line between drug, device, and biologic do not always fit neatly into established approval pathways, and the characterization of nanomedicines—their size distribution, surface properties, stability, and degradation—demands sophisticated analytics and clear regulatory guidance that is still evolving [34]. The absence of standardized methods and reference materials has historically slowed translation, and the emergence of follow-on or 'nanosimilar' products raises further questions about demonstrating equivalence. These translational and regulatory dimensions are examined in detail in Chapter 19.

Economic and access considerations are equally consequential. The high cost of developing and manufacturing advanced delivery systems, particularly personalized and cell-based therapies, raises serious concerns about affordability and equitable access, especially in low- and middle-income settings [28,31]. Reimbursement frameworks struggle to accommodate one-time, high-cost therapies, and the sustainability of pharmaceutical manufacturing—including solvent use and emerging concerns over persistent chemicals—has become an additional consideration. Table 1.4 summarizes these principal barriers. Overcoming them requires not only technical ingenuity but coordinated progress in manufacturing science, regulatory policy, and health economics.

Table 1.4. Principal challenges in the clinical adoption and commercialization of advanced delivery systems.

Challenge domain	Description	Primary impact
Manufacturing & scale-up	Reproducing nanoscale, multicomponent assembly at commercial scale	Cost, variability, delayed translation
Characterization & QC	Complex analytics for size, surface, stability, and degradation	Regulatory burden; comparability difficulties
Regulatory pathways	Products spanning drug–device–biologic categories; evolving guidance	Approval uncertainty and delay
Cost & reimbursement	High development and production costs, especially for personalized therapies	Limited affordability and access
Equity & sustainability	Global access disparities; environmental footprint of manufacturing	Restricted reach; societal scrutiny

1.15 Future Perspectives in Precision Therapeutic Platforms

The trajectory of drug delivery points toward increasingly integrated, intelligent, and personalized platforms in which the historically separate functions of diagnosis, therapy, delivery, and monitoring converge. One clear direction is the deepening fusion of nanotechnology and biotechnology, exemplified by programmable nucleic acid carriers that can be reconfigured for new targets simply by changing the encoded sequence, and by hybrid systems that combine the manufacturability of synthetic carriers with the biological sophistication of cell-derived vesicles [15,20]. The programmability of these platforms promises to compress development timelines and to support rapid responses to emerging diseases.

A second direction is the incorporation of computation and data science into every stage of delivery, from the in silico design and optimization of carriers to the use of digital twins and machine learning for personalized dose selection and the prediction of release behaviour [35]. Artificial intelligence is increasingly applied to formulation development and to the navigation of the vast design space of nanocarriers, and its integration with high-throughput experimentation and continuous manufacturing is expected to accelerate both discovery and production, as discussed in Chapter 11. A third direction is the rise of closed-loop and autonomous systems that sense a physiological signal and deliver drug accordingly, integrating responsive materials, sensors, and connected devices into self-regulating therapeutic platforms [27,28].

Realizing these visions will require sustained progress on the unglamorous but decisive problems of manufacturing, characterization, regulation, and cost identified above, as well as continued deepening of the biological understanding on which rational delivery depends [24,28]. The history surveyed in this chapter offers grounds for measured optimism: each generation of delivery technology has solved problems once thought intractable, and the convergence of disciplines now underway is without precedent. The future of drug delivery lies not in any single technology but in the intelligent integration of many, oriented around the needs of the individual patient.

1.16 Conclusion

The evolution of drug delivery, from conventional dosage forms to precision therapeutic platforms, is a story of cumulative problem-solving in which each advance arose from the limitations of its predecessor and was enabled by parallel progress in polymer science, nanotechnology, biotechnology, and computation. Conventional immediate-release formulations established the foundation of pharmaceutics but left unresolved the problems of fluctuating exposure, poor bioavailability, lack of selectivity, and adherence burden. Modified- and controlled-release systems addressed the temporal dimension of these problems; targeting strategies and nanotechnology addressed the spatial dimension; and smart, programmable, and precision platforms now address the responsiveness and personalization of therapy [1,3,4].

Contemporary practice already reflects this maturation, with approved nanomedicines, long-acting injectables, antibody–drug conjugates, nucleic acid therapeutics, and cell-based treatments delivering tangible clinical benefit, while the dramatic success of lipid nanoparticle–enabled vaccines has demonstrated the strategic importance of delivery technology to global health [20,21]. Significant challenges in manufacturing, characterization, regulation, cost, and access remain, and their resolution will determine how widely the benefits of advanced delivery are realized. The chapters that follow build directly on the conceptual framework established here, examining in detail the carrier platforms, enabling technologies, advanced modalities, site-specific strategies, and translational considerations that together constitute the frontiers of modern drug delivery.

References

1. Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951–967.
2. Hoffman AS. The origins and evolution of “controlled” drug delivery systems. J Control Release. 2008;132(3):153–163.
3. Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014;190:3–8.
4. Tibbitt MW, Dahlman JE, Langer R. Emerging frontiers in drug delivery. J Am Chem Soc. 2016;138(3):704–717.
5. Anselmo AC, Mitragotri S. An overview of clinical and commercial impact of drug delivery systems. J Control Release. 2014;190:15–28.
6. Langer R, Folkman J. Polymers for the sustained release of proteins and other macromolecules. Nature. 1976;263(5580):797–800.
7. Peppas NA, Narasimhan B. Mathematical models in drug delivery: how modeling has shaped the way we design new drug delivery systems. J Control Release. 2014;190:75–81.
8. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655–672.
9. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347–360.
10. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–252.

11. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.

12. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–1268.

13. Stewart SA, Domínguez-Robles J, Donnelly RF, Larrañeta E. Implantable polymeric drug delivery devices: classification, manufacture, materials, and clinical applications. Polymers (Basel). 2018;10(12):1379.

14. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760.

15. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124.

16. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.

17. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20–37.

18. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update. Bioeng Transl Med. 2019;4(3):e10143.

19. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.

20. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.

21. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.

22. Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomater Res. 2019;23:8.

23. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–1365.

24. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951.

25. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6(4):351–370.

26. Poon W, Kingston BR, Ouyang B, Ngo W, Chan WCW. A framework for designing delivery systems. Nat Nanotechnol. 2020;15(9):819–829.

27. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013;12(11):991–1003.

28. Sun W, Hu Q, Ji W, Wright G, Gu Z. Leveraging physiology for precision drug delivery. Physiol Rev. 2017;97(1):189–225.

29. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1:16071.

30. Fenton OS, Olafson KN, Pillai PS, Mitchell MJ, Langer R. Advances in biomaterials for drug delivery. Adv Mater. 2018;30(29):1705328.

31. Anselmo AC, Mitragotri S. Nanoparticles in the clinic: an update post COVID-19 vaccines. Bioeng Transl Med. 2021;6(3):e10246.

32. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387.

33. Germain M, Caputo F, Metcalfe S, et al. Delivering the power of nanomedicine to patients today. J Control Release. 2020;326:164–171.

34. Đorđević S, Gonzalez MM, Conejos-Sánchez I, et al. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022;12(3):500–525.

35. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916.

36. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2013;42(3):1147–1235.

37. Vallet-Regí M, Schüth F, Lozano D, Colilla M, Manzano M. Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades? Chem Soc Rev. 2022;51(13):5365–5451.

38. Mitragotri S, Anderson DG, Chen X, et al. Accelerating the translation of nanomaterials in biomedicine. ACS Nano. 2015;9(7):6644–6654.

Citation: Panjala. Mounika, Maroju. Vasudha. Molecular Dynamics Simulations: Force Fields, Sampling Techniques and Drug Design Applications. *Comprehensive Approaches in Computer-Aided Drug Design: QSAR, Docking, Screening, Homology, Pharmacophore and AI-Driven Insights.* Genome Publication. 2025; Pp155-170.
https://doi.org/10.61096/9788199887565_1